Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
American Journal of Hematology · 2024-08 · 99 (8) · 1550-1559
DOI: 10.1002/ajh.27400 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 06.06.2024. Verfasst von Paola Guglielmelli und 18 weiteren Autor:innen. Beteiligte Einrichtung: CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, DMSC, University of Florence, AOU Careggi, Florence, Italy. Hauptthemen laut MEDLINE: Janus Kinase 2, Polycythemia Vera, Thrombocythemia, Essential, Pyrazoles. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Ministero della Salute, The Italian Foundation for Cancer Research - AIRC.
Abstract (Originalsprache)
The variant allele frequency (VAF) of driver mutations ( JAK2, CALR ) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long‐term impact of molecular responses (MR) remains debated. We prospectively measured changes in JAK2 and CALR VAF in 77 patients with polycythemia vera and essential thrombocythemia, treated with ruxolitinib for a median of 8 years, and assessed correlation with complete clinical and hematological response (CCHR) and outcomes. At last observation time, JAK2 VAF reduced overall from a median of 68% (range, 20%–99%) to 3.5% (0%–98%). A profound and durable MR (DMR; defined as a VAF stably ≤2%), including complete MR in 8%, was achieved in 20% of the patients, a partial MR (PMR; VAF reduction >50% of the baseline level) in 25%, and 56% had no molecular response (NMR). A CCHR was reached by 69% overall, independently of any degree of MR achieved; conversely, a DMR correlated with longer duration of CCHR and, most importantly, with reduced rate of progression to myelofibrosis and with longer myelofibrosis‐free, event‐free and progression‐free survival. Achievement of PMR also had some favorable impact on outcomes, compared to NMR. A baseline JAK2 VAF
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, DMSC, University of Florence, AOU Careggi, Florence, Italy.
- S.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Laboratory of Cytogenetics and Molecular Biology, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
- Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milan, Italy.
ORCID-Profile: Francesco Mannelli, Giuseppe Gaetano Loscocco, Tiziano Barbui, Alessandro M Vannucchi
Förderung
- Ministero dell'Università e della Ricerca
- Ministero della Salute
- The Italian Foundation for Cancer Research - AIRC
- European Union-NextGenerationEU, PNRR «THE» (Tuscany health ecosystem), Spoke 6: Precision Medicine & Personalized Healthcare
- Ministry of health, Italia
- MUR
Zitieren
APA
Guglielmelli, P., Mora, B., Gesullo, F., Mannelli, F., Loscocco, G. G., Signori, L., Pessina, C., Colugnat, I., Aquila, R., Balliu, M., Maccari, C., Romagnoli, S., Paoli, C., Nacca, E., Fagiolo, L., Maffioli, M., Barbui, T., Passamonti, F., & Vannucchi, A. M. (2024). Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 99(8), 1550-1559. https://doi.org/10.1002/ajh.27400
Vancouver
Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. American Journal of Hematology. 2024;99(8):1550-1559. doi:10.1002/ajh.27400
BibTeX
@article{Guglielmelli2024,
author = {Guglielmelli, Paola and Mora, Barbara and Gesullo, Francesca and Mannelli, Francesco and Loscocco, Giuseppe Gaetano and Signori, Leonardo and Pessina, Chiara and Colugnat, Ilaria and Aquila, Raffaela and Balliu, Manjola and Maccari, Chiara and Romagnoli, Simone and Paoli, Chiara and Nacca, Elena and Fagiolo, Lorenzo and Maffioli, Margherita and Barbui, Tiziano and Passamonti, Francesco and Vannucchi, Alessandro M},
title = {Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {8},
pages = {1550--1559},
doi = {10.1002/ajh.27400}
}
EUVIMED